Bullock: not ruling out rate hike or cuts
Bullock says RBA not ruling anything in or out regarding rate cuts and hikes, after holds cash rate. Bullock says November hike ‘not a mistake’, and RBA doesn’t want to cut too early. ASX 200 ends lower.
Cochlear
Cochlear sticks to profit guidance
CEO Dig Howitt says there is still significant, unmet and addressable clinical need for cochlear and acoustic implants, underpinning the company’s growth.
ASX halves gains on hawkish RBA; Bapcor tanks
RBA November meeting ‘live’ as hints at hike. Santos lifts on LNG split calls. Bapcor dives as revenue growth slows. ACCC nod to NBN Co pricing. Fiery last AGM for Telstra chair John Mullen.
Cochlear declares end to the pandemic and hangover surgeries
The hearing implant titan forecasts profit growth of 16 to 23 per cent in the year ahead as surgeries return to normal following three pandemic-plagued years.
ASX climbs on wages, RBA data; Lake top gainer
CSL, Pro Medicus, Cochlear lead health sector rally. AUD at US65c after lower quarterly wages growth. China reveals more economic weakness. NAB spikes on buyback. Seek tumbles.
ASX health small caps dishing out dividends
Small cap health stocks commonly don’t pay dividends. But these ASX players have been handing out – not burning through – cash.
Cochlear’s bid to buy Oticon faces UK red light
Britain’s competition watchdog was due to deliver its final assessment early this week on Cochlear’s acquisition of Oticon Medical, and the deal was shaping up to get the red light.
Google, Cochlear harness AI to help people hear again
Peter Jackson used AI to reveal ‘secret’ conversations between The Beatles in the Get Back documentary. Cochlear and Google plan to bring that technology to those hard of hearing.
‘Sensible’ workers know the risks of bumper wage rises
Cochlear boss Dig Howitt says its wage bill hasn’t risen in line with inflation and employees understand the economics at play, as Philip Lowe issues a stern warning about big pay rises.
Banks push ASX to biggest fall in six weeks
Bourse at four-week low. CBA margins prompt selling of banks. Corporate Travel, Treasury Wine dives on misses. Cochlear jumps on buyback. Star rockets 14 per cent.
Journal sings Kazia anti-cancer drug’s praises
The potential of Kazia Therapeutics’ cancer-fighting drug EVT801 has been hailed in a scientific journal, as the company runs a clinical trial.
ASX ends up 1pc; miners gain as energy stocks slip
ASX closes at seven-month high. Warrego gives Beach Energy five days to match Hancock’s ‘superior’ offer, iron ore posts record monthly rise and Woodside leads energy losses.
Notable success in medical technology
Medical technology and medical devices is an advanced area of research, development and manufacturing in which Australia has a strong record.
Gathering seeks change of climate in China relations
Executives from a host of Australian and Chinese companies will meet in Canberra next week to discuss ways to use climate change to boost business ties with China.
Nation’s biggest health companies vow to cut carbon footprint
Australia’s biggest health companies are launching a range of strategies to cut carbon emissions, saying environmental goals are “inextricably linked” to healthcare.
Love Island and The Simpsons – how Cochlear will lift its profit 10pc this year
Hearing implants are becoming more mainstream, even featuring on The Simpsons and Love Island. Cochlear CEO Dig Howitt plans to ride the wave.
Medical device stocks that could soar from tailwinds
With strong tailwinds behind them, medical devices stocks are ready to reach new heights. Here’s why they’re set for healthy profits.
Cochlear takes long-term view on China
Hearing implant giant Cochlear is pressing ahead with its China’s plant despite increasing tensions between Canberra and Beijing.
ASX drops; Costa, Cochlear rally in bleak session
ASX led lower by tech and discretionary stocks. Nanosonics falls on profit slump, Cochlear and Costa leap of earnings, Coles profit dips and Tyro sell off continues.
Biotechs applaud tax cut move to keep Aussie research
The federal government’s ‘patent box’ will almost halve the tax rate on Australian research that is commercialised locally.
Original URL: https://www.theaustralian.com.au/topics/cochlear/page/2